NCT02483715View on ClinicalTrials.gov

Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection

PHASE4CompletedINTERVENTIONAL

Enrollment

589

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

May 31, 2018

Conditions

Helicobacter Pylori Infection

Interventions

DRUG

High-dose dual therapy (rabeprazole, amoxicillin)

High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)

DRUG

Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)

Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)

Trial Locations (1)

10002

National Taiwan University Hospital, Taipei

All Listed Sponsors

lead

National Taiwan University Hospital

OTHER

NCT02483715 - Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection | Biotech Hunter | Biotech Hunter